RetinalGenix Technologies Inc. announced the addition of Fred Chasalow, Ph.D., to the Medical Advisory Board of DNA-GPS?. He will also advise RTGN on its other corporate activities. In this capacity, specifically, he will (a) participate in therapeutic drug selection and development and (b) assist in linking high-resolution retinal imaging (RetinalCam?) both to systemic disease and to DNA-GPS?

pharmacogenetic mapping. Dr. Chasalow earned his Ph.D. in biochemistry at Brandeis University. He served as a post-doctoral fellow at ALZA and then as a Senior Research Associate at Columbia P&S with Dr. Seymour Lieberman.

From 1977 to 1995, Dr. Chasalow served at several academic appointments, finally ending as Professor of Pediatrics at SUNY, Brooklyn, and Chief of Pediatric Research at Maimonides Medical Center and Director of its Pediatric Endocrine Laboratory. During this period, much of his research included establishing diagnostic methods appropriate for small samples available from infants. In 1991, Dr. Chasalow was appointed as a member of the SuperGen Scientific Advisory Board and played a key role in the scientific development of SuperGen, leading to its successful IPO in 1996.

His business experience includes a short stint as an Associate Vice President at Morgan Stanley and 15 years as an independent financial advisor. In 1995, Dr. Chasalow was one of the founders of AMUR Research. It was in his capacity as Chief Scientific Officer that Dr. Chasalow started the investigation that led to the discovery of three novel steroids.

Later, AMUR was sold to SuperGen. In 2015, Dr. Chasalow founded IOMA LLC. At IOMA, Dr. Chasalow is credited with discovering three novel steroids.

These play a key role in the disease process leading to pre-eclampsia syndrome and, potentially, may lead to its therapy. This spring, Dr. Chasalow sold IOMA to Coddle Creek Capital, where he continues to serve as a consultant.